Genetic polymorphism of matrix metalloproteinase family and chronic obstructive pulmonary disease susceptibility: A meta-analysis

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Zhou, Hongbin ^a   Wu, Yinfang ^a   Jin, Yan ^a   Zhou, Jiesen ^a   Zhang, Chao ^a   Che, Luanqing ^a   Jing, Jiyong ^a   Chen, Zhihua ^a   Li, Wen ^a   Shen, Huahao ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE;

ALLELE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; META ANALYSIS; METABOLISM; MULTIGENE FAMILY; PUBLISHING; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASES; MULTIGENE FAMILY; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84885138143     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02818     Document Type: Article

References (48)

1. Decramer, M., Janssens, W& Miravitlles, M. Chronic obstructive pulmonary disease. Lancet 379, 1341-1351 (2012).
2. Foreman, M. G., Campos, M. & Celedón, J. C. Genes and chronic obstructive pulmonary disease. Med Clin North Am 96, 699-711 (2012).
3. Zitka, O. et al.Matrix metalloproteinases. CurrMed Chem 17, 3751-3768 (2010).
4. Churg, A. et al. An MMP-9/-12 inhibitor prevents smoke-Induced emphysema and small airway remodeling in guinea pigs. Thorax 62, 706-713 (2007).
5. Churg, A. et al. Alpha1-Antitrypsin suppresses TNF-A and MMP-12 production by cigarette smoke-Stimulated macrophages. Am J Respir Cell Mol Biol 37, 144-151 (2007).
6. Le Que?ment, C. et al. The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol 154, 1206-1215 (2008).
7. Mercer, B. A., Wallace, A. C., Brinckerhoff, C. E. & D?Armiento, J. M. Identification of a cigarette smoke-Responsive region in the distal MMP-1 promoter. Am J Respir Cell Mol Biol 40, 4-12 (2009).
8. Atkinson, J. J. et al. The role of matrix metalloproteinase-9 in cigarette smokeinduced emphysema. Am J Respir Crit Care Med 183, 876-884 (2011).
9. D?Armiento, J., Dalal, S. S., Okada, Y., Berg, R. A. & Chada, K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 71, 955-961 (1992).
10. Hautamaki, R. D., Kobayashi, D. K., Senior, R. M. & Shapiro, S. D. Macrophage elastase is required for cigarette smoke-Induced emphysema inmice. Science 277, 2002-2004 (1997).
11. Nerusu, K. C. et al. Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. Exp. Mol. Pathol 83, 169-176 (2007).
12. Cai, J., Wang, L. & Wang, A. MMP-1 gene polymorphsim and COPD susceptibility in Han nationality in Jiangxi province. Shandong Medical Journal 50, 76-77 (2010).
13. Cheng, S. L., Yu, C. J. & Yang, P. C. Genetic polymorphisms of cytochrome p450 and matrix metalloproteinase in chronic obstructive pulmonary disease. Biochem Genet 47, 591-601 (2009).
14. Van Diemen, C. C. et al. Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-Based cohorts. Respir Res 12, 57 (2011).
15. Enewold, L., Mechanic, L. E., Bowman, E.D., Platz, E. A. & Alberg, A. J. Association ofMatrixMetalloproteinase-1 Polymorphisms with Risk of COPD and Lung Cancer and Survival in Lung Cancer. Anticancer Res 32, 3917-3922 (2012).
16. Han, W., Kuang, J. & Rao, W. MMP-9 polymorphisms and susceptibility to chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis 29, 277-278 (2006).
17. Haq, I. et al. Association of MMP-2 polymorphisms with severe and very severe COPD: A case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet 11, 7-12 (2010).
18. Hersh, C. P. et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 33, 71-78 (2005).
19. Hua, D. et al. Association of MMP9 polymorphisms with susceptibility to chronic obstructive pulmonary disease in Ethnic Tibetan population. Int J Respir 30, 1157-1160 (2010).
20. Ito, I. et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 172, 1378-1382 (2005).
21. Korytina, G. F., Akhmadishina, L. Z., Ianbaeva, D. G. & Viktorova, T. V. Polymorphism in Promoter Regions of Matrix Metalloproteinases (MMP1, MMP9, and MMP12) in Chronic Obstructive Pulmonary Disease Patients. Russian Journal of Genetics 44, 202-208 (2008).
22. Korytina, G. F. et al. Association of MMP3, MMP9, ADAM33, and TIMP3 Polymorphisms with Chronic Obstructive Pulmonary Disease and Its Progression. Molecular Biology 46, 438-449 (2012).
23. Lee, S. Y. et al. Polymorphisms inmatrix metalloproteinase-1,-9 and-12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration 80, 133-138 (2010).
24. Minematsu, N.,Nakamura, H., Tateno, H.,Nakajima, T.&Yamaguchi, K.Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 289, 116-119 (2001).
25. Santus, P. et al. Stromelysin-1 polymor- phism as a new potential risk factor in progression of chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 71, 15-20 (2009).
26. Schirmer, H., Basso da Silva, L., Moreira, J. S., Moreira, A. L. & Simon, D. Matrix metalloproteinase gene polymorphisms: Lack of association with chronic obstructive pulmonary disease in a Brazilian population. Genet Mol Res 8, 1028-1034 (2009).
27. Sun, P., Chen, J., Chen, R., Jin, J. & Li, Y. The relevance of matrixmetalloproteinase-1 gene polymorphism with chronic obstructive pulmonary disease susceptibility in Han nationality of northern China. Chin J Respir Crit Care Med 4, 342-344 (2005).
28. Sun, C., Wang, W., Yang, J., Siqingaowa & Wang, L. The association of matrix metalloproteinase 3,12 polymorphism with susceptibility of chronic obstructive pulmonary disease. Chin J CIinicians (EIectronic Edition) 6, 5826-5830 (2012).
29. Tesfaigzi, Y. et al. Genotypes in matrix metalloproteinase 9 are risk factors for COPD. Int J Chron Obstruct Pulmon Dis 1, 267-278 (2006).
30. Zhang, R. et al. Matrix metalloproteinase polymorphisms and susceptibility to chronic obstructive pulmonary disease in Han nationality of north China. Journal of Cardiovascular and Pulmonary Diseases 23, 240-243 (2004).
31. Zhang, R.,He, Q., Yang, R., Lu, B.&Liu, Y. Study on matrix metalloproteinase 1, 9, 12 polymorphisms and susceptibility to chronic obstructive pulmonary disease among Han nationality in Northern China. Chin J Epidemiol 26, 907-910 (2005).
32. Zhou, M. et al. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 117, 1481-1484 (2004).
33. Pillai, S. G. et al. A genome-Wide association study in chronic obstructive pulmonary disease (COPD): Identification of two major susceptibility loci. PLoS Genet 5, e1000421 (2009).
34. Cho, M. H. et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 42, 200-202 (2010).
35. Kong, X. et al. Genome-Wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med 183, 43-49 (2011).
36. Churg, A., Zhou, S.&Wright, J. L. Matrix metalloproteinases in COPD. Eur Respir J 39, 197-209 (2012).
37. Demedts, I. K. et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 61, 196-201 (2006).
38. Vornooy, J. H. J., Lindeman, J. H. N., Jacobs, J. A., Hanemaaijer, R. & Wouters, E. F. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 126, 1802-1810 (2004).
39. Culpitt, S. V., Rogers, D. F., Traves, S. L., Barnes, P. J. & Donnelly, L. E. Sputum matrix metalloproteases: Comparison between chronic obstructive pulmonary disease and asthma. Respir Med 99, 703-710 (2005).
40. Louhelainen, N. et al. Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: A research study. BMC Pulm Med 10, 13 (2010).
41. Joos, L. et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 11, 569-576 (2002).
42. Hunninghake, G. M. et al. MMP12, lung function, and COPD in high-Risk populations. N Engl J Med 361, 2599-2608 (2009).
43. Higgins, J. P.&Thompson, S.G.Quantifying heterogeneity in ameta analysis. Stat Med 21, 1539-1558 (2002).
44. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-Analyses. BMJ 327, 557-560 (2003).
45. Wang, J. H. et al. Polymorphisms of matrix metalloproteinases in myocardial infarction: A meta-Analysis. Heart 97, 1542-1546 (2011).
46. Yan, F. G. et al. Association between polymorphism of glutathione S-Transferase P1 and chronic obstructive pulmonary disease: A meta-Analysis. Respiratory Medicine 104, 473-480 (2010).
47. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-1101 (1994).
48. Egger, M.,Davey, S. G.& Schneider, M. Bias in meta-Analysis detected by a simple, graphical test. BMJ 315, 629-634 (1997).